moatshark My

All holdings

Jazz Pharmaceuticals

JAZZ

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
2
In their latest 13F (Q3 2026)
See who
Value held
$14.9m
Combined value at quarter end
Last quarter
1 bought
1 sold or trimmed
Price at Q2 ’26 end
$240.97
+27.5% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-15.3%Q2 ’23
+4.4%Q3 ’23
-5.0%Q4 ’23
-2.1%Q1 ’24
-11.4%Q2 ’24
+27.5%Q2 ’26
Q2 ’23: -15.3%; Q3 ’23: +4.4%; Q4 ’23: -5.0%; Q1 ’24: -2.1%; Q2 ’24: -11.4%; Q2 ’26: +27.5%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

1Q4 ’23
1Q1 ’24
1Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
0Q3 ’25
0Q4 ’25
1Q1 ’26
2Q2 ’26
0Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 0; Q4 ’25: 0; Q1 ’26: 1; Q2 ’26: 2; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Jazz Pharmaceuticals.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Jazz Pharmaceuticals
Tweedy, Browne1.1%$14.5m$14.5mTrimmed -0.1%2 qtrs
Polen Capital Management0.0%$448k$448kNew1 qtr

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Jazz Pharmaceuticals
Bought or soldFiling
6 Oct 2026Gala Renee DPresident & CEO▼ Sold2,000$236.40$473kForm 4
1 Oct 2026Cozadd Bruce CDirector▼ Sold6,000$230.33$1.4mForm 4
10 Sep 2026Patil Neena MEVP & Chief Legal Officer▼ Sold1,200$240.94$289kForm 4
8 Sep 2026Gala Renee DPresident & CEO▼ Sold2,000$243.03$486kForm 4
1 Sep 2026Cozadd Bruce CDirector▼ Sold6,000$250.13$1.5mForm 4
27 Aug 2026Iannone RobertEVP, Global Head of R&D & CMO▼ Sold19,639$250.60$4.9mForm 4
27 Aug 2026Iannone RobertEVP, Global Head of R&D & CMO▼ Sold18,113$250.02$4.5mForm 4
27 Aug 2026Iannone RobertEVP, Global Head of R&D & CMO▼ Sold18,187$247.86$4.5mForm 4
27 Aug 2026Iannone RobertEVP, Global Head of R&D & CMO▼ Sold11,423$248.67$2.8mForm 4
27 Aug 2026Iannone RobertEVP, Global Head of R&D & CMO▼ Sold9,259$251.95$2.3mForm 4
27 Aug 2026Iannone RobertEVP, Global Head of R&D & CMO▼ Sold300$252.76$76kForm 4
3 Aug 2026Cozadd Bruce CDirector▼ Sold6,000$252.98$1.5mForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
Ireland
Financial year ends
31 December
Shares outstanding
65m at 27 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$872m2013
$1.3bn2015
$1.6bn2017
$2.2bn2019
$3.1bn2021
$3.8bn2023
$4.3bn2025
2013: $872m; 2014: $1.2bn; 2015: $1.3bn; 2016: $1.5bn; 2017: $1.6bn; 2018: $1.9bn; 2019: $2.2bn; 2020: $2.4bn; 2021: $3.1bn; 2022: $3.7bn; 2023: $3.8bn; 2024: $4.1bn; 2025: $4.3bn
Jazz Pharmaceuticals revenue and net income by year
YearRevenueNet income
2025$4.3bn−$356m
2024$4.1bn$560m
2023$3.8bn$415m
2022$3.7bn−$224m
2021$3.1bn−$330m
2020$2.4bn$239m
2019$2.2bn$523m
2018$1.9bn$447m
2017$1.6bn$488m
2016$1.5bn$397m
2015$1.3bn$330m
2014$1.2bn$58.4m
2013$872m$216m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.